Basilea Reports U.S. FDA Approval of Isavuconazole for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
Basel, Switzerland, March 9, 2015 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) approved…